AMGEN Inc
NASDAQ: AMGN
$336.94
+$0.99 (+0.3%)
Real Time Data Delayed 15 Min.
AMGN Articles
The March 13 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Published:
The February 28 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Published:
The February 14 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Published:
With billions of dollars flowing in, it has become impossible to ignore the ESG trend. These 15 top ESG stocks appear to be undervalued against the performance of the broader markets.
Published:
The January 31 data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Published:
Thursday's top analyst upgrades, downgrades and initiations included AbbVie, Biogen, Boeing, Etsy, Gilead Sciences, GoPro, Micron Technology, Newmont, Peloton Interactive, Pfizer, Valero Energy and...
Published:
Monday's top analyst upgrades, downgrades and initiations included Aimmune Therapeutics, Amgen, Biogen, Chevron, CRISPR, Exxon Mobil, Nike, Snap, Uber, Ulta Beauty and Verizon.
Published:
Friday's top analyst upgrades, downgrades and initiations included Amazon.com, Amgen, Coca-Cola, Danaher, Electronic Arts, IBM, Proofpoint, Sprint, UPS, Uber, Vertex Pharmaceuticals and Visa.
Published:
The January 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Published:
24/7 Wall St. has put together a preview of the most prominent earnings reports this week, including Amazon.com, AT&T and General Electric.
Published:
Why Credit Suisse believes that this round of quarterly biotech earnings could prove to be a catalyst for 2020.
Published:
The December 31 short interest data has been compared with the previous report, and short interest in these selected biotech stocks increased.
Published:
The December 13 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Published:
Christmas Eve's top analyst upgrades, downgrades and initiations included Amgen, Apple, Builder FirstSource, CarMax, Dominion Energy, FedEx, Nike, Regeneron Pharmaceuticals and Sarpeta Therapeutics.
Published:
The FDA has approved Allergan's treatment for migraines in adults. The drug is the first of its class to obtain FDA approval, but the new drug will compete with other recently released treatments for...
Published: